Infera — AI-Native Laboratory Operating System

Infera builds an AI-native compiler and operating system for laboratories that converts natural language descriptions of experiments into validated protocols, material orders, instrument execution, and data analysis. Founded in 2026 and headquartered in San Francisco, the company is backed by Y Combinator (Spring 2026 batch).

• Founded: 2026
• HQ: San Francisco, CA
• Sector: AI × Biology / Laboratory Automation
• Funding Stage: Y Combinator Seed / Accelerator-backed
• Notable Backers: Y Combinator

Core Data Grid

Infera Leadership & Structural Breakdown

• Key Leadership: Chloe Sow (Co-Founder) — background building research software and medical devices at Harvard Medical School, Brigham and Women’s Hospital, Fred Hutch, and PNNL; Mechanical Engineering + Computer Science, Harvard. Troy Zhang (Founder) — Dual BS in Political Science and Computation & Neural Systems, Caltech; R. H. Cox Research Fellow in a Nobel Prize-winning lab.

• Primary Competitors: Strateos, Emerald Cloud Lab, Benchling

• Core Use Cases & Market Problem: Academic and core research facilities seeking to automate wet lab workflows without extensive custom coding or dedicated automation engineers; smaller biotech teams aiming to reduce manual protocol translation time between experimental design and physical execution.

Explanation

Infera lets scientists describe what they want to do in everyday language (“run this proteomics workflow on these samples with these parameters”). The system handles protocol validation, material ordering, instrument control, and initial data analysis in one integrated flow.

Target Customers & Adoption Context

Primary users are academic labs, university core facilities, and early-stage biotech teams that currently spend significant time manually converting protocols into machine instructions or relying on limited automation staff. The natural language interface targets the adoption barrier that has kept advanced lab automation concentrated in large pharmaceutical or well-funded core facilities.

Capital & Traction Signals

Y Combinator Spring 2026 acceptance and standard accelerator funding provide initial capital and network access. The company is actively recruiting research labs for its pilot program, with emphasis on proteomics, genomics, flow cytometry, and automation cores. Founding team combines deep domain experience in research software, medical devices, and computational biology from top institutions.

Investor Lens

Infera sits at the execution layer of the broader 2026 AI-biology infrastructure buildout, where in silico design tools increasingly need reliable bridges to physical wet lab systems. The natural language compiler approach could meaningfully expand the addressable market for lab automation beyond large centralized facilities. Strong technical pedigree from Harvard and Caltech, combined with YC validation, provides credible early signals for a pre-product company in a capital-intensive domain. Momentum will depend on successful pilot execution and breadth of instrument compatibility. Key watchpoints for allocators include hardware integration risk across heterogeneous lab environments and the timeline to demonstrated reproducibility in real research settings. The opportunity carries asymmetric potential if the interface layer becomes a standard abstraction for automated biology workflows, though the company remains at a very early stage with limited public traction data beyond accelerator backing.

Last Updated: June 2026

Sources

• Y Combinator company page (infera)
• infera.bio
• LinkedIn company and founder profiles
• Dealroom and PitchBook references